The final, formatted version of the article will be published soon.
REVIEW article
Front. Immunol.
Sec. Microbial Immunology
Volume 16 - 2025 |
doi: 10.3389/fimmu.2025.1538127
This article is part of the Research Topic Unveiling Distinctions: Active Tuberculosis versus Latent Tuberculosis Infection - Immunological Insights, Biomarkers, and Innovative Approaches View all articles
The Importance of Inflammatory Biomarkers in Detecting and Managing Latent Tuberculosis Infection
Provisionally accepted- National Institute of Research in Tuberculosis (ICMR), Chennai, India
Infection with Mycobacterium tuberculosis (Mtb) triggers an autoimmune response in the host leading to further complications. One of the major concerns in eliminating Tuberculosis (TB) is identifying individuals with Latent Tuberculosis Infection (LTBI) who serve as major reservoirs of Mtb making them the important target group for TB eradication. Since no gold standard tests are available for detecting LTBI, the global burden of LTBI cannot be precisely determined. Since LTBI poses several challenges to worldwide healthcare, managing LTBI must be the key priority to achieve a TB-free status. The inflammatory mediators play a major role in determining the outcome of the Mtb infection and also their levels seem to change according to the disease severity. Identification of inflammatory mediators and utilizing them as diagnostic biomarkers for detecting the various stages of TB disease might help identify the reservoirs of Mtb infection even before they become symptomatic so that preventative treatment can be started early. In summary, this review primarily focuses on exploring different inflammatory markers along the course of the Mtb infection. Identifying LTBI-specific biomarkers helps to identify individuals who are at higher risk of developing TB and preparing them to adhere to preventive therapy thus minimizing the global burden of TB.
Keywords: Tuberculosis, biomarker, Latent TB, Inflammation, cytokine, chemokine, acute phase proteins
Received: 03 Dec 2024; Accepted: 17 Jan 2025.
Copyright: © 2025 Gunasekaran, Ranganathan and Bethunaickan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Ramalingam Bethunaickan, National Institute of Research in Tuberculosis (ICMR), Chennai, India
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.